{"id":58869,"date":"2026-03-05T15:58:01","date_gmt":"2026-03-05T07:58:01","guid":{"rendered":"https:\/\/flcube.com\/?p=58869"},"modified":"2026-03-05T15:58:02","modified_gmt":"2026-03-05T07:58:02","slug":"astragenomics-and-kactus-forge-gene-editing-partnership-global-commercial-rights-and-manufacturing-scale-up-for-nucleic-acid-therapeutics","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=58869","title":{"rendered":"AstraGenomics and Kactus Forge Gene Editing Partnership \u2013 Global Commercial Rights and Manufacturing Scale-Up for Nucleic Acid Therapeutics"},"content":{"rendered":"\n<p><strong>AstraGenomics<\/strong> and <strong>Kactus<\/strong> announced a <strong>strategic collaboration agreement<\/strong> to accelerate development and commercialization of <strong>nucleic acid drugs and gene editing technologies<\/strong>. Under terms, AstraGenomics granted Kactus <strong>global rights to manufacture and commercialize<\/strong> its innovative gene editing tools, combining breakthrough platform science with industrial\u2011scale production capabilities to advance genome editing solutions for research, therapeutics, and biomanufacturing.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-partnership-structure\">Partnership Structure<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Element<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Deal Type<\/strong><\/td><td>Strategic collaboration with manufacturing and commercialization rights<\/td><\/tr><tr><td><strong>Licensor<\/strong><\/td><td>AstraGenomics (gene editing platform)<\/td><\/tr><tr><td><strong>Licensee<\/strong><\/td><td>Kactus (recombinant protein manufacturing)<\/td><\/tr><tr><td><strong>Scope<\/strong><\/td><td>Global rights for manufacture and commercialization<\/td><\/tr><tr><td><strong>Technology Focus<\/strong><\/td><td>Nucleic acid drugs, gene editing tools<\/td><\/tr><tr><td><strong>Target Markets<\/strong><\/td><td>Research, therapeutics, biomanufacturing<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-technology-platforms\">Technology Platforms<\/h2>\n\n\n\n<p><strong>AstraGenomics Capabilities:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Systematic Platform:<\/strong> Integration of computational biology and laboratory automation<\/li>\n\n\n\n<li><strong>Toolbox Portfolio:<\/strong><\/li>\n\n\n\n<li><strong>Transposon\u2011based systems:<\/strong> Large fragment gene writing technologies<\/li>\n\n\n\n<li><strong>Nuclease\u2011based systems:<\/strong> Precision editing tools<\/li>\n\n\n\n<li><strong>Innovation Focus:<\/strong> Breakthrough platform yielding plentiful tool systems for complex genomic modifications<\/li>\n<\/ul>\n\n\n\n<p><strong>Kactus Capabilities:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Core Expertise:<\/strong> High\u2011quality recombinant proteins for biotherapeutic development<\/li>\n\n\n\n<li><strong>SAMS R&amp;D Platform:<\/strong> Proprietary system for protein engineering and optimization<\/li>\n\n\n\n<li><strong>Manufacturing Infrastructure:<\/strong> cGMP\u2011compliant facilities enabling clinical\u2011grade production<\/li>\n\n\n\n<li><strong>Value Proposition:<\/strong> Conversion of cutting\u2011edge innovations into reliable, high\u2011activity commercial products<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-rationale-amp-market-impact\">Strategic Rationale &amp; Market Impact<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Factor<\/th><th>Implication<\/th><\/tr><\/thead><tbody><tr><td><strong>Platform Synergy<\/strong><\/td><td>AstraGenomics&#8217; discovery engine + Kactus&#8217; manufacturing scale creates end\u2011to\u2011end gene editing supply chain<\/td><\/tr><tr><td><strong>Global Access<\/strong><\/td><td>Kactus&#8217; commercial infrastructure accelerates worldwide availability of advanced editing tools<\/td><\/tr><tr><td><strong>Therapeutic Pipeline<\/strong><\/td><td>Enables faster IND\u2011enabling studies for nucleic acid drug candidates<\/td><\/tr><tr><td><strong>Biomanufacturing<\/strong><\/td><td>Standardized gene editing tools support cell and gene therapy manufacturing workflows<\/td><\/tr><tr><td><strong>Competitive Positioning<\/strong><\/td><td>Combined entity challenges established players (Thermo Fisher, Synthego, ToolGen) in Asia\u2011Pacific gene editing market<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Revenue Model:<\/strong> Kactus to pay milestones and royalties on commercialized products; AstraGenomics retains co\u2011development rights for proprietary therapeutic programs<\/li>\n\n\n\n<li><strong>Standardization Push:<\/strong> Collaboration aims to establish industry standards for large\u2011fragment gene writing quality control and batch consistency<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-industry-context\">Industry Context<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Gene Editing Market:<\/strong> Global market projected to exceed <strong>$15\u202fbillion by 2028<\/strong>, driven by CRISPR therapeutics and cell therapy manufacturing demand<\/li>\n\n\n\n<li><strong>Supply Chain Gap:<\/strong> shortage of GMP\u2011grade editing enzymes constrains IND timelines; this partnership addresses manufacturing bottleneck<\/li>\n\n\n\n<li><strong>Geographic Expansion:<\/strong> Positions both companies for ex\u2011China partnerships with Western biotechs seeking validated Asian manufacturing partners<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding partnership milestones, technology commercialization, and market expansion for the AstraGenomics\u2011Kactus collaboration. Actual results may differ due to technology transfer challenges, regulatory requirements for GMP manufacturing, and competitive dynamics in the gene editing tools market.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>AstraGenomics and Kactus announced a strategic collaboration agreement to accelerate development and commercialization of nucleic&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[4640,66,2429],"class_list":["post-58869","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-astragenomics","tag-gene-therapy","tag-kactus-biosystems"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>AstraGenomics and Kactus Forge Gene Editing Partnership \u2013 Global Commercial Rights and Manufacturing Scale-Up for Nucleic Acid Therapeutics - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"AstraGenomics and Kactus announced a strategic collaboration agreement to accelerate development and commercialization of nucleic acid drugs and gene editing technologies. Under terms, AstraGenomics granted Kactus global rights to manufacture and commercialize its innovative gene editing tools, combining breakthrough platform science with industrial\u2011scale production capabilities to advance genome editing solutions for research, therapeutics, and biomanufacturing.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=58869\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AstraGenomics and Kactus Forge Gene Editing Partnership \u2013 Global Commercial Rights and Manufacturing Scale-Up for Nucleic Acid Therapeutics\" \/>\n<meta property=\"og:description\" content=\"AstraGenomics and Kactus announced a strategic collaboration agreement to accelerate development and commercialization of nucleic acid drugs and gene editing technologies. Under terms, AstraGenomics granted Kactus global rights to manufacture and commercialize its innovative gene editing tools, combining breakthrough platform science with industrial\u2011scale production capabilities to advance genome editing solutions for research, therapeutics, and biomanufacturing.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=58869\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-05T07:58:01+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-05T07:58:02+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58869#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58869\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"AstraGenomics and Kactus Forge Gene Editing Partnership \u2013 Global Commercial Rights and Manufacturing Scale-Up for Nucleic Acid Therapeutics\",\"datePublished\":\"2026-03-05T07:58:01+00:00\",\"dateModified\":\"2026-03-05T07:58:02+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58869\"},\"wordCount\":420,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"AstraGenomics\",\"Gene therapy\",\"Kactus Biosystems\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=58869#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58869\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=58869\",\"name\":\"AstraGenomics and Kactus Forge Gene Editing Partnership \u2013 Global Commercial Rights and Manufacturing Scale-Up for Nucleic Acid Therapeutics - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-03-05T07:58:01+00:00\",\"dateModified\":\"2026-03-05T07:58:02+00:00\",\"description\":\"AstraGenomics and Kactus announced a strategic collaboration agreement to accelerate development and commercialization of nucleic acid drugs and gene editing technologies. Under terms, AstraGenomics granted Kactus global rights to manufacture and commercialize its innovative gene editing tools, combining breakthrough platform science with industrial\u2011scale production capabilities to advance genome editing solutions for research, therapeutics, and biomanufacturing.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58869#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=58869\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58869#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AstraGenomics and Kactus Forge Gene Editing Partnership \u2013 Global Commercial Rights and Manufacturing Scale-Up for Nucleic Acid Therapeutics\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"AstraGenomics and Kactus Forge Gene Editing Partnership \u2013 Global Commercial Rights and Manufacturing Scale-Up for Nucleic Acid Therapeutics - Insight, China&#039;s Pharmaceutical Industry","description":"AstraGenomics and Kactus announced a strategic collaboration agreement to accelerate development and commercialization of nucleic acid drugs and gene editing technologies. Under terms, AstraGenomics granted Kactus global rights to manufacture and commercialize its innovative gene editing tools, combining breakthrough platform science with industrial\u2011scale production capabilities to advance genome editing solutions for research, therapeutics, and biomanufacturing.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=58869","og_locale":"en_US","og_type":"article","og_title":"AstraGenomics and Kactus Forge Gene Editing Partnership \u2013 Global Commercial Rights and Manufacturing Scale-Up for Nucleic Acid Therapeutics","og_description":"AstraGenomics and Kactus announced a strategic collaboration agreement to accelerate development and commercialization of nucleic acid drugs and gene editing technologies. Under terms, AstraGenomics granted Kactus global rights to manufacture and commercialize its innovative gene editing tools, combining breakthrough platform science with industrial\u2011scale production capabilities to advance genome editing solutions for research, therapeutics, and biomanufacturing.","og_url":"https:\/\/flcube.com\/?p=58869","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-03-05T07:58:01+00:00","article_modified_time":"2026-03-05T07:58:02+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=58869#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=58869"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"AstraGenomics and Kactus Forge Gene Editing Partnership \u2013 Global Commercial Rights and Manufacturing Scale-Up for Nucleic Acid Therapeutics","datePublished":"2026-03-05T07:58:01+00:00","dateModified":"2026-03-05T07:58:02+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=58869"},"wordCount":420,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["AstraGenomics","Gene therapy","Kactus Biosystems"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=58869#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=58869","url":"https:\/\/flcube.com\/?p=58869","name":"AstraGenomics and Kactus Forge Gene Editing Partnership \u2013 Global Commercial Rights and Manufacturing Scale-Up for Nucleic Acid Therapeutics - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-03-05T07:58:01+00:00","dateModified":"2026-03-05T07:58:02+00:00","description":"AstraGenomics and Kactus announced a strategic collaboration agreement to accelerate development and commercialization of nucleic acid drugs and gene editing technologies. Under terms, AstraGenomics granted Kactus global rights to manufacture and commercialize its innovative gene editing tools, combining breakthrough platform science with industrial\u2011scale production capabilities to advance genome editing solutions for research, therapeutics, and biomanufacturing.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=58869#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=58869"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=58869#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"AstraGenomics and Kactus Forge Gene Editing Partnership \u2013 Global Commercial Rights and Manufacturing Scale-Up for Nucleic Acid Therapeutics"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/58869","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=58869"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/58869\/revisions"}],"predecessor-version":[{"id":58870,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/58869\/revisions\/58870"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=58869"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=58869"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=58869"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}